Feinberg
Northwestern Medicine | Northwestern University | Faculty Profiles

News Center

  • Categories
    • Campus News
    • Disease Discoveries
    • Clinical Breakthroughs
    • Education News
    • Scientific Advances
  • Press Releases
  • Media Coverage
  • Podcasts
  • Editor’s Picks
    • COVID-19
    • Cardiology
    • Cancer
    • Neurology and Neuroscience
    • Aging and Longevity
    • Artificial Intelligence in Medicine
  • News Archives
  • About Us
    • Media Contact
    • Share Your News
    • News Feeds
    • Social Media
    • Contact Us
Menu
  • Categories
    • Campus News
    • Disease Discoveries
    • Clinical Breakthroughs
    • Education News
    • Scientific Advances
  • Press Releases
  • Media Coverage
  • Podcasts
  • Editor’s Picks
    • COVID-19
    • Cardiology
    • Cancer
    • Neurology and Neuroscience
    • Aging and Longevity
    • Artificial Intelligence in Medicine
  • News Archives
  • About Us
    • Media Contact
    • Share Your News
    • News Feeds
    • Social Media
    • Contact Us
Home » Revived Drug May Serve as New Parkinson’s Treatment
Disease Discoveries

Revived Drug May Serve as New Parkinson’s Treatment

By Will DossOct 23, 2019
Share
Facebook Twitter Email
Joseph Mazzulli, PhD, assistant professor in the Ken and Ruth Davee Department of Neurology in the Division of Movement Disorders, was the senior author of the study.

A cancer drug that failed to show benefit in clinical trials for cancer more than 15 years ago may have the potential to slow the progression of Parkinson’s disease, according to a Northwestern Medicine study published in Neuron.

The small molecule drug appears to help jump-start lysosomal function, which in turn clears out harmful proteins that build up and lead to Parkinson’s symptoms, according to Joseph Mazzulli, PhD, assistant professor in the Ken and Ruth Davee Department of Neurology in the Division of Movement Disorders and senior author of the study.

“We started trying to figure out why cells die in Parkinson’s disease,” Mazzulli said. “We came up with this new protein called ykt6 as a therapeutic target and we discovered a way to activate this protein with a small molecule.”

A defining characteristic of Parkinson’s disease is the accumulation of misfolded alpha-synuclein proteins in the brain. These proteins aggregate and form clumps which are linked to a variety of harmful effects including oxidative stress, inflammation and mitochondrial dysfunction.

Previous studies have noted that while other misfolded proteins are usually destroyed by the lysosome, an organelle that is responsible for waste disposal in the cell, Parkinson’s linked-protein aggregates have been shown to be curiously resistant to this mechanism.

Aggregated a-Synuclein protein (yellow) accumulates inside nerve endings of Parkinson’s disease patient cultures causing degeneration.

In the current study, Mazzulli and his collaborators discovered that protein aggregates depress lysosomal function by impeding lysosomal protein trafficking — in essence, intercepting the garbage trucks before they empty the dumpster. Normally, cells can cope with lysosomal stress by activating ykt6, boosting lysosomal protein trafficking and helping dispose of unwanted proteins.

However, in Parkinson’s disease, alpha-synuclein binds to and deactivates ykt6, disabling the lysosomal stress response, according to Mazzulli.

“It actually impedes the cell’s ability to degrade proteins by inhibiting the trafficking of lysosomal machinery,” Mazzulli said. “Once the lysosomes are depleted, the cell can no longer degrade proteins.”

Previous studies showed that the activity of ykt6 is regulated by farnesylation, a specialized molecule that locks it in an inactive conformation. The investigators surmised that blocking the farnesylation of ykt6 could unleash its activity and boost protein disposal in patients with Parkinson’s disease, so they searched for small molecules to inhibit its farnesylation, finding one that might work: LNK-754.

“We had known farnesyl-transferase inhibitors were extensively developed for cancer therapies, but they faded as the pharmaceutical companies realized it wasn’t going to be a good strategy for inhibiting tumor growth,” Mazzulli said.

Testing this molecule in patient-derived mid-brain neuron cultures and mice modeling Parkinson’s disease, the investigators were impressed by its effectiveness: not only did the drug release ykt6, but it appeared to promote trafficking at many other steps, enhancing protein disposal.

“Basically, the highway is clogged and LNK-754 is opening up more lanes for lysosomal trafficking,” Mazzulli said.

Mice modeling Parkinson’s saw a dramatic reduction in protein aggregates when taking the drug orally and it’s active at low concentrations, both of which point to its viability as a future therapy that could head off the worst symptoms of Parkinson’s, according to Mazzulli.

“Parkinson’s often starts off with a movement disorder, but it progresses to dementia, and we think this molecule could engage this pathway and stop that progress,” Mazzulli said. “It’s a good candidate for the next stage of drug development.”

Leah Cuddy, PhD, research assistant professor of Neurology in the Division of Behavioral Neurology, was the lead author of the study.

Neurology and Neuroscience Research
Share. Facebook Twitter Email

Related Posts

Hormone Therapy Plus Current Treatments Improves Survival in Prostate Cancer

Mar 22, 2023

How ChatGPT Has, and Will Continue to, Transform Scientific Research

Mar 21, 2023

New Directions for HIV Treatment

Mar 21, 2023

Comments are closed.

Latest News

Hormone Therapy Plus Current Treatments Improves Survival in Prostate Cancer

Mar 22, 2023

How ChatGPT Has, and Will Continue to, Transform Scientific Research

Mar 21, 2023

New Directions for HIV Treatment

Mar 21, 2023

Humans are Not Just Big Mice: Identifying Science’s Muscle-Scaling Problem

Mar 20, 2023

AOA Honors New Members

Mar 20, 2023
  • News Center Home
  • Categories
  • Press Release
  • Media Coverage
  • Editor’s Picks
  • News Archives
  • About Us
Flickr Photos
20230315_NM036
20230315_NM046
20230315_NM134
20230315_NM205
20230315_NM206
20230315_NM132
20230315_NM130
20230315_NM082
20230315_NM063
20230315_NM058
20230315_NM030
20230315_NM038

Northwestern University logo

Northwestern University Feinberg School of Medicine

RSS Facebook Twitter LinkedIn Flickr YouTube Instagram
Copyright © 2023 Northwestern University
  • Contact Northwestern University
  • Disclaimer
  • Campus Emergency Information
  • Policy Statements

Type above and press Enter to search. Press Esc to cancel.